The Crown corporation says the repayable funding will help it maintain operations but would not help in its structural issues as it faces consistent financial losses.
Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.